Want to submit or suggest content for the MiMedia Clinical Library?
Contact us here
EPG Online is not responsible for external content
Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.
| Drug class description : | Taxanes. |
| Generic Name : | Paclitaxel |
| Drug description : | Vials containing 30mg, 100mg or 300mg in vials as a 6mg/mL solution. |
| Presentation : | Infusion, paclitaxel 6 mg /mL. |
| Indications : | Primary treatment of advanced or residual ovarian cancer in combination with cisplatin. Secondary treatment of metastatic ovarian cancer where platinum therapy has failed. Metastatic breast cancer where anthracycline therapy has failed or is inappropriate. Non-small cell lung cancer in combination with cisplatin where surgery or radiation is inappropriate. |
| Adult Dosage : | Primary treatment of ovarian cancer, 135 mg/m2 by intravenous infusion over 24 hours followed by cisplatin 75 mg/m 2, with a three-week interval between courses. Secondary treatment of ovarian and breast cancer, 175 mg/m 2 by intravenous infusion over 3 hours, with a three-week 3 hours, with a three-week interval between courses. Non-small cell lung cancer, 175 mg/m2 by intravenous infusion over 3 hours followed by cisplatin 80 mg/m2, with a three-week interval between courses. Pretreat with corticosteroids, antihistamines and H - antagonists; see Summary of 2 Product Characteristics. |
| Child Dosage : | Not applicable. |
| Contra Indications : | Severe hypersensitivity to paclitaxel or any ingredient, especially polyethoxylated castor oil. Neutrophils < 1.5 x 10 9 per litre. Pregnancy, lactation. |
| Special Precautions : | Monitor blood counts. Cardiac conduction abnormalities, peripheral neuropathy. Not recommended in severe hepatic impairment. |
| Interactions : | Administer before cisplatin. |
| Adverse Reactions : | Myelosuppression, peripheral neuropathy (reduce dose if severe); alopecia, arthralgia, myalgia, hypotension, bradycardia, GI disturbances, elevations in liver function tests, oedema, inj. site reactions. Rarely hypersensitivity reactions (ensure supportive equipment available), cardiovascular conduction abnormalities. |
| Manufacturer : | Bristol-Myers Squibb |
| Drug Availability : | (POM) |
Only registered users have access to the full EPG Online Knowledge Base including drug search tools, interactive disease Knowledge Centres via the EPG Knowledge Library - with clinical and evidence based physician and research tools, MiMedia (build your own clinical media collection with everything from key opinion leader essays to mode of action videos and other multi-media content), the EPG Survey panel, health news updates and much much more.
Already Registered?
Please log-in now using our member login box.
Not a member?
Don't worry, registration is quick and FREE! We welcome all Healthcare professionals, doctors, nurses and medical students.
Register today to have full access to a wealth of drug data, educational and evidence based interactive guides across all major therapeutic areas, disease management, and clinical tools.
As a practicing Healthcare professional, you can also opt-in to join our market research panel – www.epgsurvey.com – and get paid for sharing your expert clinical opinions!
REGISTER today it only takes a minute! and it's FREE
Having problems?
Use our forgotten password facility or email us at: contact@epgonline.org